Your Title Goes Here

Defining the genomic architecture of Age-related Macular Degeneration (AMD) to improve diagnosis, prevention, and treatment.

For patients and families:  About genetic testing or participating in clinical trials for age-related macular degeneration

Multiple studies have provided compelling evidence that common genetic variants can account for about 70% of the hereditary component for AMD.

Highly penetrant rare risk alleles have also been identified which carry a very high likelihood of the development of AMD and have been particularly valuable in understanding the biology of the condition.

 If you or someone you love would like to learn more about clinical trials and how to participate, you may want to contact your ophthalmologist or neurologist who can direct you to studies in your area.



Contact us:

Susan Halloran Blanton, PhD

Project Manager, IAMDGC